Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €34.07 EUR
Change Today +0.30 / 0.89%
Volume 15.3K
ERYP On Other Exchanges
EN Paris
As of 7:50 AM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

erytech pharma (ERYP) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/5/15 - €35.38
52 Week Low
08/8/14 - €12.12
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ERYTECH PHARMA (ERYP)

Related News

No related news articles were found.

erytech pharma (ERYP) Related Businessweek News

No Related Businessweek News Found

erytech pharma (ERYP) Details

ERYTECH Pharma, société anonyme develops cancer therapies. The company’s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. It is developing ERY-ASP that consists of red blood cell-encapsulated L-asparaginase, which destroys asparagine inside the red blood cell, preventing allergic reactions and reducing other adverse events. The company is developing ERY-ASP for the treatment of acute lymphoblastic leukaemia, acute myeloid leukaemia, and solid tumours. The company was founded in 2004 and is headquartered in Lyon, France.

Founded in 2004

erytech pharma (ERYP) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: €335.5K
Co-Founder, Chief Scientific Officer, Deputy ...
Total Annual Compensation: €243.1K
Director of Pharmaceutical Operations and Dep...
Total Annual Compensation: €65.9K
Compensation as of Fiscal Year 2014.

erytech pharma (ERYP) Key Developments

Erytech Pharma Société Anonyme Presents at BioEquity Europe 2015, May-19-2015 05:00 PM

Erytech Pharma Société Anonyme Presents at BioEquity Europe 2015, May-19-2015 05:00 PM. Venue: InterContinental Vienna, Vienna, Austria.

ERYTECH Pharma Reports Cash Flow Results for the First Quarter of 2015

ERYTECH Pharma reported cash flow results for the first quarter of 2015. For the first quarter of 2015, the company reported net use of cash for operational and investing activities amounted to EUR 3.0 million for the quarter, compared to EUR 2.4 million during the first quarter of last year. These results are in line with the expectations and the strategy of the company which in 2015 remains focused on the clinical development of its innovative treatments for acute leukemia and other oncology indications in Europe and in the United States.

Erytech Pharma Société Anonyme Presents at Boston CEO Conference, May-26-2015 04:30 PM

Erytech Pharma Société Anonyme Presents at Boston CEO Conference, May-26-2015 04:30 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Gil Beyen, Chairman and Chief Executive Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ERYP:FP €34.07 EUR +0.30

ERYP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ERYP.
View Industry Companies

Industry Analysis


Industry Average

Valuation ERYP Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ERYTECH PHARMA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at